These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

418 related items for PubMed ID: 19644623

  • 1. Retention rates of disease-modifying anti-rheumatic drugs in patients with rheumatoid arthritis.
    Agarwal S, Zaman T, Handa R.
    Singapore Med J; 2009 Jul; 50(7):686-92. PubMed ID: 19644623
    [Abstract] [Full Text] [Related]

  • 2. Impact of initial aggressive drug treatment with a combination of disease-modifying antirheumatic drugs on the development of work disability in early rheumatoid arthritis: a five-year randomized followup trial.
    Puolakka K, Kautiainen H, Möttönen T, Hannonen P, Korpela M, Julkunen H, Luukkainen R, Vuori K, Paimela L, Blåfield H, Hakala M, Leirisalo-Repo M.
    Arthritis Rheum; 2004 Jan; 50(1):55-62. PubMed ID: 14730599
    [Abstract] [Full Text] [Related]

  • 3. Contemporary disease modifying antirheumatic drugs (DMARD) in patients with recent onset rheumatoid arthritis in a US private practice: methotrexate as the anchor drug in 90% and new DMARD in 30% of patients.
    Sokka T, Pincus T.
    J Rheumatol; 2002 Dec; 29(12):2521-4. PubMed ID: 12465145
    [Abstract] [Full Text] [Related]

  • 4. Methotrexate, hydroxychloroquine, and intramuscular gold in rheumatoid arthritis: relative area under the curve effectiveness and sequence effects.
    Hurst S, Kallan MJ, Wolfe FJ, Fries JF, Albert DA.
    J Rheumatol; 2002 Aug; 29(8):1639-45. PubMed ID: 12180722
    [Abstract] [Full Text] [Related]

  • 5. Effectiveness profiles and dose dependent retention of traditional disease modifying antirheumatic drugs for rheumatoid arthritis. An observational study.
    Aletaha D, Smolen JS.
    J Rheumatol; 2002 Aug; 29(8):1631-8. PubMed ID: 12180721
    [Abstract] [Full Text] [Related]

  • 6. The methotrexate therapeutic response in rheumatoid arthritis.
    Ortendahl M, Holmes T, Schettler JD, Fries JF.
    J Rheumatol; 2002 Oct; 29(10):2084-91. PubMed ID: 12375316
    [Abstract] [Full Text] [Related]

  • 7. Toward a definition and method of assessment of treatment failure and treatment effectiveness: the case of leflunomide versus methotrexate.
    Wolfe F, Michaud K, Stephenson B, Doyle J.
    J Rheumatol; 2003 Aug; 30(8):1725-32. PubMed ID: 12913927
    [Abstract] [Full Text] [Related]

  • 8. Contemporary use of disease-modifying drugs in the management of patients with early rheumatoid arthritis in Norway.
    Nikolaisen C, Kvien TK, Mikkelsen K, Kaufmann C, Rødevand E, Nossent JC.
    Scand J Rheumatol; 2009 Aug; 38(4):240-5. PubMed ID: 19229766
    [Abstract] [Full Text] [Related]

  • 9. Effectiveness and retention rates of methotrexate in psoriatic arthritis in comparison with methotrexate-treated patients with rheumatoid arthritis.
    Lie E, van der Heijde D, Uhlig T, Heiberg MS, Koldingsnes W, Rødevand E, Kaufmann C, Mikkelsen K, Kvien TK.
    Ann Rheum Dis; 2010 Apr; 69(4):671-6. PubMed ID: 19740904
    [Abstract] [Full Text] [Related]

  • 10. Disappointing longterm results with disease modifying antirheumatic drugs. A practice based study.
    Galindo-Rodriguez G, Aviña-Zubieta JA, Russell AS, Suarez-Almazor ME.
    J Rheumatol; 1999 Nov; 26(11):2337-43. PubMed ID: 10555887
    [Abstract] [Full Text] [Related]

  • 11. Factors influencing length of time taking methotrexate in rheumatoid arthritis.
    Ortendahl M, Schettler JD, Fries JF.
    J Rheumatol; 2000 May; 27(5):1139-47. PubMed ID: 10813279
    [Abstract] [Full Text] [Related]

  • 12. Real-world effectiveness of select biologic and DMARD monotherapy and combination therapy in the treatment of rheumatoid arthritis: results from the RADIUS observational registry.
    Weaver AL, Lautzenheiser RL, Schiff MH, Gibofsky A, Perruquet JL, Luetkemeyer J, Paulus HE, Xia HA, Leff JA, RADIUS Investigators.
    Curr Med Res Opin; 2006 Jan; 22(1):185-98. PubMed ID: 16393444
    [Abstract] [Full Text] [Related]

  • 13. Step-up combination versus switching of non-biological disease-modifying antirheumatic drugs in rheumatoid arthritis: results from a retrospective observational study.
    Schoels M, Kapral T, Stamm T, Smolen JS, Aletaha D.
    Ann Rheum Dis; 2007 Aug; 66(8):1059-65. PubMed ID: 17307765
    [Abstract] [Full Text] [Related]

  • 14. Patient, disease, and therapy-related factors that influence discontinuation of disease-modifying antirheumatic drugs: a population-based incidence cohort of patients with rheumatoid arthritis.
    Maradit-Kremers H, Nicola PJ, Crowson CS, O'Fallon WM, Gabriel SE.
    J Rheumatol; 2006 Feb; 33(2):248-55. PubMed ID: 16358365
    [Abstract] [Full Text] [Related]

  • 15. Low-dose prednisolone in rheumatoid arthritis: adverse effects of various disease modifying antirheumatic drugs.
    Malysheva OA, Wahle M, Wagner U, Pierer M, Arnold S, Häntzschel H, Baerwald CG.
    J Rheumatol; 2008 Jun; 35(6):979-85. PubMed ID: 18412314
    [Abstract] [Full Text] [Related]

  • 16. Response-driven combination therapy with conventional disease-modifying antirheumatic drugs can achieve high response rates in early rheumatoid arthritis with minimal glucocorticoid and nonsteroidal anti-inflammatory drug use.
    Proudman SM, Keen HI, Stamp LK, Lee AT, Goldblatt F, Ayres OC, Rischmueller M, James MJ, Hill CL, Caughey GE, Cleland LG.
    Semin Arthritis Rheum; 2007 Oct; 37(2):99-111. PubMed ID: 17391739
    [Abstract] [Full Text] [Related]

  • 17. The good initial response to therapy with a combination of traditional disease-modifying antirheumatic drugs is sustained over time: the eleven-year results of the Finnish rheumatoid arthritis combination therapy trial.
    Rantalaiho V, Korpela M, Hannonen P, Kautiainen H, Järvenpää S, Leirisalo-Repo M, Hakala M, Puolakka K, Julkunen H, Luosujärvi R, Möttönen T, FIN-RACo Trial Group.
    Arthritis Rheum; 2009 May; 60(5):1222-31. PubMed ID: 19404945
    [Abstract] [Full Text] [Related]

  • 18. Initial disease modifying antirheumatic drugs and prednisolone prescriptions for patients with rheumatoid arthritis: a 15-year study.
    Osiri M, Akkasilpa S, Deesomchok U.
    J Med Assoc Thai; 2000 Mar; 83(3):217-24. PubMed ID: 10808674
    [Abstract] [Full Text] [Related]

  • 19. Longterm methotrexate use in rheumatoid arthritis: 12 year followup of 460 patients treated in community practice.
    Wluka A, Buchbinder R, Mylvaganam A, Hall S, Harkness A, Lewis D, Littlejohn GO, Miller MH, Ryan PF.
    J Rheumatol; 2000 Aug; 27(8):1864-71. PubMed ID: 10955325
    [Abstract] [Full Text] [Related]

  • 20. Early suppression of disease activity is essential for maintenance of work capacity in patients with recent-onset rheumatoid arthritis: five-year experience from the FIN-RACo trial.
    Puolakka K, Kautiainen H, Möttönen T, Hannonen P, Korpela M, Hakala M, Järvinen P, Ahonen J, Forsberg S, Leirisalo-Repo M, FIN-RACo Trial Group.
    Arthritis Rheum; 2005 Jan; 52(1):36-41. PubMed ID: 15641055
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 21.